Zhang Financial LLC Has $390,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Zhang Financial LLC raised its holdings in Bristol-Myers Squibb (NYSE:BMY) by 9.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,395 shares of the biopharmaceutical company’s stock after acquiring an additional 569 shares during the quarter. Zhang Financial LLC’s holdings in Bristol-Myers Squibb were worth $390,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in BMY. Alpha Omega Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 1.5% in the first quarter. Alpha Omega Wealth Management LLC now owns 30,130 shares of the biopharmaceutical company’s stock valued at $1,838,000 after purchasing an additional 439 shares during the period. Capital Advisory Group Advisory Services LLC raised its position in shares of Bristol-Myers Squibb by 5.1% in the first quarter. Capital Advisory Group Advisory Services LLC now owns 12,735 shares of the biopharmaceutical company’s stock valued at $777,000 after purchasing an additional 614 shares during the period. Focus Financial Network Inc. raised its position in shares of Bristol-Myers Squibb by 6.5% in the first quarter. Focus Financial Network Inc. now owns 4,068 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 248 shares during the period. Donaldson Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 3.5% in the first quarter. Donaldson Capital Management LLC now owns 61,445 shares of the biopharmaceutical company’s stock valued at $3,748,000 after purchasing an additional 2,050 shares during the period. Finally, Bard Financial Services Inc. raised its position in shares of Bristol-Myers Squibb by 4.2% in the first quarter. Bard Financial Services Inc. now owns 41,065 shares of the biopharmaceutical company’s stock valued at $2,505,000 after purchasing an additional 1,665 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Up 1.0%

BMY opened at $50.68 on Friday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm’s fifty day moving average price is $48.78 and its two-hundred day moving average price is $54.83. The company has a market capitalization of $103.14 billion, a P/E ratio of -11.47, a P/E/G ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the company earned ($4.40) earnings per share. The business’s revenue was down 5.6% compared to the same quarter last year. On average, analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BMY shares. UBS Group dropped their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 target price on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Finally, Jefferies Financial Group dropped their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.